Buy this ASX 200 stock for a 21% return: Broker

Big returns could be on the cards for buyers of this stock according to Bell Potter.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Australian share market has traditionally delivered an average annual return of around 10%.

While that is a great return, the team at Bell Potter thinks you could potentially double this return with the ASX 200 stock in this article.

Excited couple celebrating success while looking at smartphone.

Image source: Getty Images

Which ASX 200 stock?

The stock that Bell Potter is recommending to clients is ALS Ltd (ASX: ALQ).

It is a global testing, inspection, and certification (TIC) company, servicing clients across several industries.

Bell Potter notes that ALS commands a market-leading position in geochemical testing, leveraging its hub-and-spoke model, Laboratory Information Management System (LIMS) and innovative value-added capabilities.

In Life Sciences, it operates one of the largest global environmental testing businesses, with a footprint spanning 35+ countries.

It released its full-year results on Monday and delivered numbers that were largely in line with Bell Potter's expectations. It said:

ALQ's FY26 result was headlined by uEBIT of $599m, up 19.3% YoY and in line with BPe. Group uEBIT margin expanded 130bps to 18.0% (BPe 17.5%).

Key points: Operating result: Group organic revenue growth of +8.4% (BPe +9.1%), was led by Commodities (+18.1%; BPe +16.6%), with mixed performance reported at Life Sciences (+2.8%; BPe +4.8%). Expanding exploration activity in 2H across Junior, Intermediate and Major customers delivered an acceleration in sample volume growth and improved pricing dynamics, with lower-priced legacy contacts rolling off as guided.

It also notes that its guidance for FY 2027 was also in line with expectations. The broker adds:

Outlook commentary include: 1) FY27 Minerals organic revenue expected to rise 13.0-15.0% YoY (BPe old 14.5%), with 1H FY27 uEBIT margin to be consistent with 2H FY26 levels, then rising a further 30-50bps in 2H FY27; and 2) Life Sciences targeting mid-single digit organic revenue growth in FY27 (BPe old 4.6%), with incremental EBIT margin improvement of 30-50bps (BPe old 44bps).

Big potential returns

According to the note, Bell Potter has retained its buy rating on the ASX 200 stock with a trimmed price target of $26.00 (from $28.00).

Based on its current share price of $21.83, this implies potential upside of 19% for investors over the next 12 months.

In addition, a partially franked 2.3% dividend yield is expected in FY 2027, boosting the total potential return to approximately 21%.

Commenting on its buy recommendation, Bell Potter said:

Our downgraded Target Price reflects a higher WACC of 8.3% (previously 7.8%). We view the FY27 Minerals revenue and EBIT margin outlook as conservative, with FY26 exit-rates and exploration market indicators suggesting Minerals could deliver organic revenue growth of >20.0% in FY27 (BPe new 14.9% – within guidance).

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

A male investor wearing a white shirt and blue suit jacket sits at his desk looking at his laptop with his hands to his chin, waiting in anticipation.
Broker Notes

Should you buy this ASX 200 share after it crashed 23%?

Let's see if Bell Potter thinks this weakness has created a buying opportunity.

Read more »

Female pharmacist smiles with a digital tablet.
Broker Notes

3 reasons to buy Sigma Healthcare shares today

A leading analyst expects “impressive growth” from Sigma Healthcare shares.

Read more »

Business man marking Sell on board and underlining it
Broker Notes

Why experts are selling these 3 ASX shares this week

These shares have been given sell ratings. But why?

Read more »

A woman sits at her computer with her chin resting on her hand as she contemplates her next potential investment.
Broker Notes

Buy, hold, sell: ResMed, Sigma, and TechnologyOne shares

Are analysts bullish on these popular stocks? Let's see what they are saying this week.

Read more »

Man drawing an upward line on a bar graph symbolising a rising share price.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Here's why brokers believe that now could be the time to buy these shares.

Read more »

Red sell button on an Apple keyboard.
Broker Notes

Sell alert! Why this expert is calling time on Technology One shares

A leading analyst foresees growing headwinds for Technology One shares.

Read more »

A man in his 30s with a clipped beard sits at his laptop on a desk with one finger to the side of his face and his chin resting on his thumb as he looks concerned while staring at his computer screen.
Broker Notes

Buy, hold, sell: James Hardie, NextDC, and WiseTech shares

Analysts have given their verdict on these popular shares this week.

Read more »

A woman holds her finger to the side of her face and looks upwards as she thinks about something.
Broker Notes

Buy, hold, sell: Catapult Sports, Worley, CBA shares

ASX 200 shares deteriorated last week and are in the red for 2026 to date.

Read more »